Erratum

Erratum. Aspirin for the Primary Prevention of Cardiovascular Events. A Systematic Review and Meta-Analysis Comparing Patients With and Without Diabetes. Diabetes Care 2009;32:2300–2306

https://doi.org/10.2337/dc18-er06a

In the article cited above, Fig. 2 should have shown the pooled relative risks and 95% CI for the effect of aspirin versus control on death, myocardial infarction, and ischemic stroke, respectively, stratified by diabetes status of the trial participants. The published version of the manuscript incorrectly labeled the plots. In verifying every data point on the figure, the authors found discrepancies on the values reported for the Early Treatment Diabetic Retinopathy Study (ETDRS), particularly in the denominators used, which should have reported 1,856 patients with diabetes allocated to aspirin and 1,855 participants without diabetes allocated to placebo. The authors are grateful to the colleagues who noted this discrepancy and brought it to their attention and for the opportunity, almost a decade later, to correct the published record. The corrected Fig. 2 (3 panels) and the corrected legend are published below.

Andrew D. Calvin, Niti R. Aggarwal, Mohammad Hassan Murad, Qian Shi, Mohamed B. Elamin, Jeffrey B. Geske, M. Merce Fernandez-Balsells, Felipe N. Albuquerque, Julianna F. Lampropulos, Patricia J. Erwin, Steven A. Smith, and Victor M. Montori



study	ASA		Placebo		RR (95% CI)	% Weigh
Sludy	ASA		FIACEDO		KK (55% CI)	weign
Diabetes						
HOT	40	752	36	749	1.11 (0.71, 1.72)	4.02
JPAD	34	1262	38	1277 😽	0.91 (0.57, 1.43)	3.72
POPADAD	116	638	117	638 -	0.99 (0.79, 1.25)	14.34
PPP	25	519	20	512	1.23 (0.69, 2.19)	2.34
ETDRS	340	1856	366	1855 🔶	0.93 (0.81, 1.06)	43.80
Subtotal (I-squared = 0.0%, p = 0.825)						
No Diabetes						
APLASA	1	44	1	48 🗲	 1.09 (0.07, 16.92 	0.10
HOT	244	8647	269	8642	- 0.91 (0.76, 1.08)	26.54
PPP	42	1849	61	1904	0.71 (0.48, 1.04)	5.14
Subtotal (I-squared = 0.0%, p = 0.517)						
Overall (I-squared = 0.0%, p = 0.801)					0.93 (0.85, 1.02)	100.0
				1		

Subgroup interaction: p=0.31

В

Myocardial infarction


%

						%
study	ASA		Placebo		RR (95% CI)	Weight
Diabetes				1		
нот	11	752	18	749	0.61 (0.29, 1.28)	4.48
JPAD	12	1262	14	1277 -	0.87 (0.40, 1.87)	4.27
POPADAD	90	638	82	638	1.10 (0.83, 1.45)	12.86
PPP	5	519	10	512	0.49 (0.17, 1.43)	2.48
ETDRS	241	1856	283	1855 🔶	0.85 (0.73, 1.00)	16.19
WHS	36	538	24	499 -	1.39 (0.84, 2.30)	7.62
PHS	11	275	26	258 -	0.40 (0.20, 0.79)	5.06
Subtotal (I-squar	ed = 54.0%	0.85 (0.66, 1.10)	52.97			
				1		
No Diabetes						
нот	71	8647	109	8642 📥	0.65 (0.48, 0.88)	12.33
PPP	15	1849	22	1904 -	0.70 (0.37, 1.35)	5.41
PHS	128	10750	213	10763 🔶	0.60 (0.48, 0.75)	14.60
WHS	162	19396	169	19443	0.96 (0.78, 1.19)	14.69
Subtotal (I-squar	ed = 69.7%	0.72 (0.55, 0.94)	47.03			
Overall (I-square	d = 62.8%,	0.79 (0.66, 0.95)	100.00			
				i		
				.5	1 2	

Subgroup interaction: p=0.38

С

Ischemic stroke



Subgroup interaction: p=0.48

Figure 2–Forest plots of random effects meta-analyses for pooled relative risks (RR) of mortality (*A*), myocardial infarction (*B*), and ischemic stroke (*C*). Results are presented for patients with and without diabetes and for all patients combined. Squares and horizontal lines represent the point estimates and associated 95% CI. The diamonds represent the pooled RR, with the center representing the point estimate and the width representing the associated 95% CI.